Hemodynamic Response After Six Months of Sildenafil

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2007 by University of Chile.
Recruitment status was  Recruiting
Information provided by:
University of Chile
ClinicalTrials.gov Identifier:
First received: June 6, 2007
Last updated: NA
Last verified: April 2007
History: No changes posted
The purpose of this study is to determine the clinical, functional and hemodynamic response after six months of sildenafil 50 mg TID in patients with pulmonary arterial hypertension.

Condition Intervention Phase
Pulmonary Arterial Hypertension
Drug: oral sildenafil
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Hemodynamic Evaluation of Patients With Pulmonary Arterial Hypertension. Response to Sildenafil Treatment

Resource links provided by NLM:

Further study details as provided by University of Chile:

Primary Outcome Measures:
  • Arterial pulmonary resistance index [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Mean pulmonary arterial pressure, Cardiac index, pulmonary saturation, walked distance, functional class. [ Time Frame: 6 months ]

Estimated Enrollment: 27
Study Start Date: August 2003
Estimated Study Completion Date: June 2007
Detailed Description:

Pulmonary arterial hypertension is a chronic devastating disease. There are few approval oral treatments. Sildenafil, a phosphodiesterase 5 inhibitors, has been recently approved for patients on functional class II and III showing hemodynamic benefits after 12 weeks of treatment. Long term hemodynamic evaluation after sildenafil treatment has not been evaluating in pulmonary arterial patients on functional class II to IV.

The protocol has been designed to evaluate patients on functional class II to IV from baseline conditions and after 6 months of sildenafil treatment (50 mg po TID). Clinical (functional class), functional (walked distance-6 minute walking test) and Hemodynamic evaluation is planned to be performed at baseline and after 6 months of treatment.


Ages Eligible for Study:   16 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients older than 15 years old with Pulmonary arterial hypertension according with WHO hemodynamic definition,
  • Who signed informed consent,
  • Able to swallow tablets and follow instructions.

Exclusion Criteria:

  • Patients with pulmonary hypertension with other categories than pulmonary arterial hypertension (associated to COPD, lund diseases, sleep apnea, thromboembolic disease, hight altitude), patients asymptomatic, patients who were responders to adenosine during hemodynamic test, patients treated with specific treatments for pulmonary arterial hypertension before started the study such as sildenafil, prostanoids, endothelin receptors blockers.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00483626

Contact: Monica M Zagolin, MD 056-2-3403505 ext 504 monizagolin@hotmail.com
Contact: Polentzi Uriarte, MD 056-2-3403505 ext 504 puriarte@alemana.cl

National Instiute of Thorax Recruiting
Santiago, Metropolitanta, Chile, 7500691
Sub-Investigator: Polentzi Uriarte, MD         
Principal Investigator: Monica M Zagolin, MD         
Sub-Investigator: Eduardo Wainsteiin, MD         
Sub-Investigator: Claudio Parra, MD         
Sponsors and Collaborators
University of Chile
Principal Investigator: Monica M Zagolin, MD National Institute of Thorax
  More Information

ClinicalTrials.gov Identifier: NCT00483626     History of Changes
Other Study ID Numbers: Thorax-001-2003 
Study First Received: June 6, 2007
Last Updated: June 6, 2007
Health Authority: Chile: Instituto de Salud Pública de Chile

Keywords provided by University of Chile:
pulmonary hypertension

Additional relevant MeSH terms:
Cardiovascular Diseases
Vascular Diseases
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Therapeutic Uses
Urological Agents
Vasodilator Agents

ClinicalTrials.gov processed this record on May 01, 2016